CCL17 and Alzheimer disease: Another study confirmed, that patients with moderate-to-severe AD treated with dupilumab significantly reduced the expression of genes involved in type 2 inflammation (IL-13, IL-31, CCL17, CCL18, and CCL26), and Th17/Th22 activity and increased expression of lipid metabolism and barrier genes (ELOVL3, loricrin (LOR), claudins, filaggrin (FLG) (47).